
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, pr... Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -0.675675675676 | 7.4 | 8.6099 | 7.11 | 38421 | 7.91780946 | CS |
4 | 0.19 | 2.65363128492 | 7.16 | 8.6099 | 5.44 | 63220 | 6.87677415 | CS |
12 | 2.55 | 53.125 | 4.8 | 19.44 | 4.06 | 623466 | 11.93721474 | CS |
26 | -1.4625 | -16.5957446809 | 8.8125 | 19.44 | 4.06 | 304786 | 11.48355502 | CS |
52 | -17.4 | -70.303030303 | 24.75 | 24.75 | 4.06 | 219958 | 12.14525118 | CS |
156 | -17.4 | -70.303030303 | 24.75 | 24.75 | 4.06 | 219958 | 12.14525118 | CS |
260 | -17.4 | -70.303030303 | 24.75 | 24.75 | 4.06 | 219958 | 12.14525118 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions